New Pancreatic Cancer Drug Daraxonrasib Delivers Landmark Phase 3 Results
TL;DR Summary
Revolution Medicines announced that its pancreatic cancer drug daraxonrasib met all primary and secondary endpoints in a Phase 3 trial, nearly doubling median overall survival (13.2 months vs 6.7 months) and reducing the risk of death by about 60% versus chemotherapy, prompting an FDA filing using a Commissioner’s National Priority Voucher; safety was manageable and the company is pursuing second-line use and trials in newly diagnosed patients.
Topics:business#daraxonrasib#health#overall-survival#pancreatic-cancer#phase-3-trial#revolution-medicines
- Revolution Medicines' potential breakthrough pancreatic cancer drug succeeds in late-stage trial CNBC
- RevMed’s Cancer Drug Nearly Doubles Overall Survival in Pivotal Study Bloomberg.com
- Revolution’s much-hyped RAS inhibitor hits key survival goals in phase 3 pancreatic cancer trial Fierce Biotech
- Revolution Medicines touts ‘unprecedented’ data for pancreatic cancer pill statnews.com
- Daraxonrasib Demonstrates Unprecedented Overall Survival GlobeNewswire
Reading Insights
Total Reads
0
Unique Readers
16
Time Saved
2 min
vs 3 min read
Condensed
85%
448 → 67 words
Want the full story? Read the original article
Read on CNBC